Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a Southern Italian hospital

Haematologica

Volumn 84, Issue 2, 1999, Pages 142-149

  Mazza, Patrizio ^b   Secondo, Emmanuela ^c   Palazzo, Giulia ^c   Amurri, Barbara ^c   Manna, Nunzia ^c   Miloro, Gianfranco ^c   Moscogiuri, Rossella ^a  

^a Serv Farmaceutico Azienda Osp S   (Italy)

^b Ospedale Nord   (Italy)

^c NONE

Author keywords

Costs; Lymphoma; PBSC

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; FEMALE; HEALTH CARE COST; HUMAN; LYMPHOMA; MALE; PROGNOSIS; RELAPSE; SAFETY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS; HUMANS; ITALY; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 0032835746     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kessinger A, Vose JM, Bierman PJ, Bishop M, Armitage JO. Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients. J Hematother 1993; 2:361-2.
2. Has R, Brittinger G, Meusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10:1975-9.
3. Corradini P, Astolfi M, Gherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non Hodgkin's lymphomas treated with high dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89:724-31.
4. Dregger P, Von Neuhoff N, Kuse R, et al. Sequential high dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8:401-3.
5. Hurd DD, Haake RJ, Lasky LC, et al. Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. Med Pediatr Oncol 1990; 18:447-53.
6. Federico M, Clo V, Carella AM. High dose therapy and autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 trial. Leukemia 1996; 10(Suppl 2):S69-S71.
7. Sweetenham JW, Tachipour G, Milligan D. et al. High dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for blood and marrow transplantation. Bone Marrow Transplant 1997; 20:745-52.
8. Majolino I, Pearce R, Tachipour G, Goldstone AH. Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for blood and marrow transplantation registry data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15:509-17.
9. Gianni AM, Bregni M, Siena S, et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336:1290-7.
10. Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified and high dose chemotherapy with granulocyte colony-stimulating factor and autologous stem cell trans-plantation support as first-line therapy in high risk large cell lymphoma. J Clin Oncol 1997; 15:491-8.
11. Fredman AS, Gribben JG, Neuberg, D, et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88:2780-6.
12. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-5.
13. Gianni AM, Bonadonna G. High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 1989; 25:1027-30.
14. Messori A, Bonistalli L, Costantini M, Alterini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19:275-81.
15. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastimmobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:5-10.
16. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126:600-7.
17. Tarella C, Castellino C, Locatelli F, et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21:401-7.
18. Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20:445-50.
19. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilized by r-metHuG-CSF (Filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 30A:1631-5.
20. Costantini M, Bonistalli L. Trapianto autologo di midollo in pazienti con linfoma non Hodgkin in ricaduta: analisi dei dati di soprawivenza e valutazione costo-efficacia. Giornale di Farmacoeconomia 1997; 1:155-60.
21. Craig JI, Anthony RS, Stewart A, Thompson EB, Gillon J, Parker AC. Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol 1993; 85:210-2.
22. Tura S, Mazza P, Gherlinzoni F, et al. High dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. Scand J Haematol 1986; 37:347-52.
23. Philip T, Armitage JO, Spitzer G, et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316:1493-8.
24. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:588-95.
25. Kanfer E. Bone marrow transplant conditioning regimen schedules. In: J. Treleaven, J. Barrett, eds. Bone Marrow Transplant in Practice. Edinburgh: Churchill Livingstone Press; 1992. p. 247-55.
26. Bennet CL, Armitage JL, Armitage GO, et al. Cost of care and outcomes for high dose therapy and autologous transplantation for lymphoid malignancies: 1997 through 1991. J Clin Oncol 1995; 13:969-73.
27. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukemia in the Netherlands. Bone Marrow Transplant 1995; 15:605-10.
28. th Meeting of the Nurses's Group. Courmayeur, Italy, March 22-26, 1998. Bone Marrow Transplant 1998; 21(suppl 1):S374.
29. th Meeting of the Nurses's Group. Courmayeur, Italy, March 22-26, 1998. Bone Marrow Transplant 1998; 21(suppl 1): S375.
30. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1023-30.
31. Koziner B, Little C. Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables. Cancer 1982; 49:1571-9.
32. Bordonaro L, Zagonel V. Fattori prognostici nei linfomi. In: Salvagno-Fiorentino, eds. Piccin. 1996. p. 247-58.
33. Philips LG, Herzig RH, Lazarus HM, et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 1984; 310:1557-61.
34. Martelli M, Vignetti M, Zinzani PL, et al. High dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line therapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14:534-42.
35. Waters TM, Bennett CL, Vose JM. Economic analyses of new technologies: the case of stem-cell transplantation. J Clin Oncol 1997; 15:2-4.
36. Decreto Legge 30/12/92 n. 502. Riordino della disciplina in materia sanitaria, a norma dell'articolo 1 della legge 23 ottobre 1992, n. 421. Art. 14. Diritti dei cittadini. Gazzetta Ufficiale n. 305 30/12/92. p. 5-22.